SPRY
ARS Pharmaceuticals·NASDAQ
--
--(--)
--
--(--)
4.01 / 10
Netural
Analyst consensus is a single Strong Buy (100%) from Roth Capital, but with zero historical win rate. Fund flow is excellent (8.03/10), showing strong inflows across most sizes except large investors. Overall sentiment is bullish yet analyst track record is weak.
Fund Flow Rating
Analyst RatingStrong Buy
Wall Street Opinions
Strong Buy
Strong Buy
100%
Buy
0%
Hold
0%
Sell
0%
Strong Sell
0%
Date2025-09-04
InstitutionRoth Capital
Times predicted1
Historical Win Rate0.0%
What is the analyst consensus for SPRY?
- SPRY holds a Bearish analyst rating, with 100% of experts assigning a Strong Buy grade. Factoring in net Inflows from order flow data, the comprehensive Sentiment Score stands at 4.01/10 (Netural).
ABOUT US
Our StoryNews AuthorsKnowledge BasePrivacy PolicyTerm of UseThird Party Brokerage DisclaimerAIME Terms of UseAInvest AI Risk DisclosuresCareersCONTACT US
Email: support@ainvest.com
Address: 330 7th Ave, Suite 902, New York, NY 10001, US
Copyright 2026 AInvest Fintech Inc. All rights reserved.
